Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Intensity Therapeutics, Inc. (INTS)
Company Research
Source: Yahoo! Finance
Cash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025 SHELTON, Conn. May 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2024 financial results and provides a corporate update. Corporate Update In mid-2024, the Company intends on initiating a Phase 3 open-label, randomized study, or the INVINCIBLE-3 Study, testing INT230-6 as a monotherapy compared to the standard of care ("SOC") drugs in second and third line treatment for certain soft tissue sarcoma subtypes. We plan to enroll 333 patients with an endpoint of overall survival and have screened and qualified over 30 sites for the INVINCIBLE-3 Study. Contract negotiations to a
Show less
Read more
Impact Snapshot
Event Time:
INTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INTS alerts
High impacting Intensity Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INTS
News
- Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
- Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of DirectorsPR Newswire
- Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug CandidatePR Newswire
- Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
INTS
Sec Filings
- 6/7/24 - Form SC
- 6/7/24 - Form 4
- 6/4/24 - Form DEFA14A
- INTS's page on the SEC website